Aerpio Pharmaceuticals, Inc.
Industry
- Biotechnology
- Pharmaceuticals
Other Names/Subsidiaries
- AADi Bioscience, LLC
- Aerpio Acquisition Corp.
Latest on Aerpio Pharmaceuticals, Inc.
Two former US Food and Drug Administration commissioners – Mark McClellan and Scott Gottlieb – are among the most recent regulatory experts to join the international chorus calling for master protocol
Three biopharmaceutical companies went public in the US on 24 October with different results – Phathom Pharmaceuticals Inc. priced its initial public offering at $19 per share, within a proposed $18
The largest start-up venture capital financing in the first quarter was completed by Anthos Therapeutics Inc. with a $250m Series A round, but Series B rounds made up the largest segment of the $3.4
Cincinnati, OH-based Aerpio Pharmaceuticals Inc. is facing a more difficult future after its lead product, AKB-9778, failed in a Phase IIb study in moderate to severe non-proliferative diabetic reti